South Korea · Delayed Price · Currency is KRW HYUNDAI BIOLAND Statistics
Total Valuation
HYUNDAI BIOLAND has a market cap or net worth of KRW 119.40 billion. The enterprise value is 99.94 billion.
| Market Cap | 119.40B |
| Enterprise Value | 99.94B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | Apr 2, 2026 |
Share Statistics
HYUNDAI BIOLAND has 30.00 million shares outstanding. The number of shares has increased by 0.06% in one year.
| Current Share Class | 30.00M |
| Shares Outstanding | 30.00M |
| Shares Change (YoY) | +0.06% |
| Shares Change (QoQ) | -0.48% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.81% |
| Float | 19.50M |
Valuation Ratios
The trailing PE ratio is 8.95.
| PE Ratio | 8.95 |
| Forward PE | n/a |
| PS Ratio | 0.85 |
| PB Ratio | 0.82 |
| P/TBV Ratio | 0.84 |
| P/FCF Ratio | 5.15 |
| P/OCF Ratio | 4.64 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.21, with an EV/FCF ratio of 4.31.
| EV / Earnings | 7.49 |
| EV / Sales | 0.71 |
| EV / EBITDA | 5.21 |
| EV / EBIT | 6.90 |
| EV / FCF | 4.31 |
Financial Position
The company has a current ratio of 5.06, with a Debt / Equity ratio of 0.04.
| Current Ratio | 5.06 |
| Quick Ratio | 2.58 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | 0.33 |
| Debt / FCF | 0.28 |
| Interest Coverage | 40.84 |
Financial Efficiency
Return on equity (ROE) is 9.53% and return on invested capital (ROIC) is 9.98%.
| Return on Equity (ROE) | 9.53% |
| Return on Assets (ROA) | 5.60% |
| Return on Invested Capital (ROIC) | 9.98% |
| Return on Capital Employed (ROCE) | 9.79% |
| Weighted Average Cost of Capital (WACC) | 8.46% |
| Revenue Per Employee | 412.61M |
| Profits Per Employee | 39.14M |
| Employee Count | 341 |
| Asset Turnover | 0.87 |
| Inventory Turnover | 1.80 |
Taxes
In the past 12 months, HYUNDAI BIOLAND has paid 1.83 billion in taxes.
| Income Tax | 1.83B |
| Effective Tax Rate | 12.08% |
Stock Price Statistics
The stock price has decreased by -10.56% in the last 52 weeks. The beta is 0.80, so HYUNDAI BIOLAND's price volatility has been lower than the market average.
| Beta (5Y) | 0.80 |
| 52-Week Price Change | -10.56% |
| 50-Day Moving Average | 3,709.80 |
| 200-Day Moving Average | 4,051.38 |
| Relative Strength Index (RSI) | 55.40 |
| Average Volume (20 Days) | 46,539 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HYUNDAI BIOLAND had revenue of KRW 140.70 billion and earned 13.35 billion in profits. Earnings per share was 444.83.
| Revenue | 140.70B |
| Gross Profit | 56.75B |
| Operating Income | 14.48B |
| Pretax Income | 15.18B |
| Net Income | 13.35B |
| EBITDA | 19.20B |
| EBIT | 14.48B |
| Earnings Per Share (EPS) | 444.83 |
Balance Sheet
The company has 25.88 billion in cash and 6.42 billion in debt, with a net cash position of 19.46 billion or 648.70 per share.
| Cash & Cash Equivalents | 25.88B |
| Total Debt | 6.42B |
| Net Cash | 19.46B |
| Net Cash Per Share | 648.70 |
| Equity (Book Value) | 145.56B |
| Book Value Per Share | 4,857.86 |
| Working Capital | 74.99B |
Cash Flow
In the last 12 months, operating cash flow was 25.71 billion and capital expenditures -2.51 billion, giving a free cash flow of 23.20 billion.
| Operating Cash Flow | 25.71B |
| Capital Expenditures | -2.51B |
| Depreciation & Amortization | 4.72B |
| Net Borrowing | -4.39B |
| Free Cash Flow | 23.20B |
| FCF Per Share | 773.24 |
Margins
Gross margin is 40.34%, with operating and profit margins of 10.29% and 9.49%.
| Gross Margin | 40.34% |
| Operating Margin | 10.29% |
| Pretax Margin | 10.79% |
| Profit Margin | 9.49% |
| EBITDA Margin | 13.64% |
| EBIT Margin | 10.29% |
| FCF Margin | 16.49% |
Dividends & Yields
This stock pays an annual dividend of 35.00, which amounts to a dividend yield of 0.88%.
| Dividend Per Share | 35.00 |
| Dividend Yield | 0.88% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | 15.73% |
| Buyback Yield | -0.06% |
| Shareholder Yield | 0.83% |
| Earnings Yield | 11.18% |
| FCF Yield | 19.43% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 17, 2024. It was a forward split with a ratio of 2.
| Last Split Date | May 17, 2024 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
HYUNDAI BIOLAND has an Altman Z-Score of 6.49 and a Piotroski F-Score of 6.
| Altman Z-Score | 6.49 |
| Piotroski F-Score | 6 |